Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback